REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

“Today’s new Phase I/II interim data demonstrates continued positive impact on function, stable cardiac health, and…